| 7.66 0.36 (4.93%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.3 |
1-year : | 10.87 |
| Resists | First : | 7.96 |
Second : | 9.3 |
| Pivot price | 7.29 |
|||
| Supports | First : | 6.96 |
Second : | 6.34 |
| MAs | MA(5) : | 7.44 |
MA(20) : | 7.24 |
| MA(100) : | 7.87  |
MA(250) : | 6.51 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 75.4 |
D(3) : | 73.3 |
| RSI | RSI(14): 56.5 |
|||
| 52-week | High : | 12.35 | Low : | 1.55 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SERA ] has closed below upper band by 7.4%. Bollinger Bands are 63.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.98 - 8.01 | 8.01 - 8.04 |
| Low: | 7.32 - 7.35 | 7.35 - 7.39 |
| Close: | 7.59 - 7.66 | 7.66 - 7.71 |
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Fri, 13 Sep 2024
Sera Prognostics President Evguenia Lindgardt Sells 26% Of Holding - Simply Wall St
Wed, 11 Sep 2024
Sera Prognostics CEO sells shares worth $189,893 - Investing.com
Wed, 11 Sep 2024
Sera prognostics CFO sells over $38k in company stock - Investing.com
Mon, 09 Sep 2024
Sera Prognostics director sells shares for tax obligations - Investing.com India
Mon, 09 Sep 2024
Encompass Health (EHC), Piedmont Expand Ties to Serve Georgia - MSN
Fri, 05 Jul 2024
Sera Prognostics added to Russell 2000 and 3000 indexes following conclusion of 2024 indexes annual reconstitution - Utah Business
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 1.97e+007 (%) |
| Held by Institutions | 12.7 (%) |
| Shares Short | 633 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.453e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -38 % |
| Return on Assets (ttm) | 554.1 % |
| Return on Equity (ttm) | -24.4 % |
| Qtrly Rev. Growth | 107000 % |
| Gross Profit (p.s.) | -75.24 |
| Sales Per Share | -41.84 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.19 |
| Price to Cash Flow | 4.57 |
| Dividend | 0 |
| Forward Dividend | 786710 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|